Clinical Trial Update: PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD [Phase 2]

View source ↗

Summary

A Phase 2 randomized trial comparing PT001 MDI to Spiriva (tiotropium) in adults with moderate to severe COPD has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• PT001 MDI
• Spiriva (tiotropium)

Snippet

Sponsor: Pearl Therapeutics, Inc. | Conditions: Chronic Obstructive Pulmonary Disease | Phase 2 | Status: COMPLETED | Results posted: 2017-10-12